Evidence map›Paper›PMID 42545577›Full record

ReviewCurrent cardiology reports2026

Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence.

Daniel Akrawi, Shayan Datta, Suzan Hatipoglu, Ashutosh D Wechalekar, Aruni Ghose, Ahmed Alkhateeb, J Malcolm Walker, Arjun K Ghosh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel AkrawiCardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
Shayan DattaCardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
Suzan HatipogluCardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
Ashutosh D WechalekarNational Amyloidosis Centre, Royal Free London NHS Foundation Trust, London, UK.
Aruni GhoseCardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
Ahmed AlkhateebCardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
J Malcolm WalkerCardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
Arjun K GhoshCardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK. arjun.ghosh@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review examines cardiovascular complications of multiple myeloma and anti-myeloma therapy, emphasising integrated systems-based cardiovascular management and the institutional model developed at the University College London Hospital Cardio-Oncology (CO) Centre of Excellence. RECENT

findingsCardiovascular vulnerability in multiple myeloma reflects baseline risk, disease-related factors, including cardiac amyloidosis, and treatment-related cardiotoxicity. A longitudinal approach should begin before therapy with multidimensional risk stratification incorporating patient, disease, and treatment factors, with intermediate- and high-risk patients referred for CO review. During treatment, active surveillance using clinical assessment, cardiac biomarkers and imaging, with vigilance for cardiac amyloidosis, enables rapid CO referral and timely intervention. Survivorship care should include annual cardiovascular review, risk-factor optimisation, and monitoring for late toxicity. Existing evidence and real-world experience support integrated CO services combining rapid-access clinics, high-volume cardiac imaging, timely decision-making, inpatient consultation, multidisciplinary collaboration, and survivorship surveillance while preserving cardiovascular health and access to effective anti-myeloma therapy.

Indexed as

Antineoplastic AgentsCardiovascular DiseasesMultiple MyelomaCardio-OncologyCardiotoxicityDelivery of Health Care, IntegratedHumansRisk AssessmentRisk FactorsUnited KingdomAntineoplastic AgentsAmyloidosisCardio-oncologyCardiovascular careCardiovascular toxicityHeart failureMultiple myeloma

Identifiers

PMID42545577

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.